Study: Ozempic May Cut Depression and Anxiety Risk

The Numbers Behind the Headline

The headline figure is the one most outlets led with, and it holds up: during periods when participants were taking semaglutide, their risk of worsening mental illness was about 42% lower than during periods when the same people were not taking it. The research, published in The Lancet Psychiatry, put the adjusted hazard ratio at 0.58, with a 95% confidence interval of 0.51 to 0.65.

When the team broke the results down by condition, the pattern stayed consistent. Semaglutide use was associated with roughly a 44% lower risk of worsening depression, a 38% lower risk of worsening anxiety, and a 47% lower risk of worsening substance use disorder. Looked at as a group, GLP-1 medications were also tied to a lower risk of self-harm.

Not every medication in the class behaved the same way, though, and that turns out to be one of the most interesting parts of the story.

A Decade of Swedish Health Records

The strength of a study like this comes from its size and its source. Rather than relying on a survey or a single clinic, the team drew on Sweden's national health registers, which quietly record hospitalizations, prescriptions, and sick leave across the whole population. They followed people from 2009 through 2022, a span long enough to watch how individuals fared across years of real life. Of the 95,490 people in the group, 22,480 used a GLP-1 medication at some point during that window, as detailed in the summary from Karolinska Institutet, the Swedish university that led the work.

The researchers were also careful about what counted as a bad outcome. "Worsening mental illness" was not a vague dip in mood; it was a composite of hard, documented events — psychiatric hospitalization, sick leave longer than 14 days for psychiatric reasons, hospitalization for self-harm, or death by suicide. Those are serious markers, which makes the size of the associations more meaningful.

Comparing People to Themselves

The most clever part of the design is something called a within-individual comparison. Instead of measuring people who took semaglutide against a different group of people who did not, the team compared each participant to themselves — their stretches on the medication versus their stretches off it. That approach quietly cancels out a lot of the noise that usually muddies this kind of research, because the things that make you you, from your genetics to your life history, stay the same whether or not you happen to be on a prescription that month. It is one of the reasons the findings carry more weight than a typical observational snapshot, even though, as you will see, they still stop short of proof.

If GLP-1 medications worked on mental health simply because they all belong to the same family, you would expect them to move together. They did not. Semaglutide showed the clearest benefit, liraglutide a more modest one, and two others — exenatide and dulaglutide — showed essentially nothing. That spread is a clue. It suggests that whatever is happening here is not a tidy class effect, and that the specifics of each molecule, or how people use it, may matter.

Researchers have a few working ideas about why semaglutide in particular might be involved, though they frame them as questions rather than answers. Some of the benefit could be indirect: better blood sugar, weight loss, and the lift in day-to-day functioning that often follows can all ripple into how a person feels. Some of it could be more direct, through the drug's effects on brain pathways tied to mood. For now, both remain hypotheses awaiting better evidence.

An Association, Not Proof

This is the part most worth slowing down for. Because the study was observational, it can show that semaglutide use and better mental-health outcomes occurred together, but it cannot establish that the medication caused the improvement. Unmeasured factors could still be playing a role, and the authors themselves are the first to say so.

That caution comes straight from the senior investigator. "Our findings suggest that GLP-1 drugs, particularly semaglutide, might contribute to better mental health in people with diabetes and obesity, but since this was an observational study, controlled clinical trials are needed to confirm the results," said Jari Tiihonen, a specialist physician and professor at the Centre for Psychiatry Research at Karolinska Institutet, who served as the study's senior author. In other words, the next step is the kind of randomized trial that can actually test cause and effect.

Who the Results Actually Apply To

It is easy for a finding like this to get stretched beyond what it can hold, so the boundaries matter. Everyone in the study already had a diagnosis of depression or anxiety, and everyone was being treated with antidiabetic medication for diabetes or obesity. That is a specific, higher-risk population. The results do not tell us how semaglutide affects mood in people without these conditions, and they say nothing about using GLP-1 medications purely for cosmetic weight loss.

Just as importantly, Ozempic and its relatives are not approved as treatments for depression or anxiety, and this study did not test them that way. It is a promising signal in a particular group of people — not a green light to think of these medications as mental-health prescriptions.

What the FDA and European Regulators Concluded

There is some helpful context here, because GLP-1 medications and mental health have a complicated recent history. A few years ago, scattered reports raised the worry that these drugs might increase suicidal thoughts, and that concern understandably rattled a lot of people. Regulators took it seriously and looked closely.

After reviewing data from 91 placebo-controlled clinical trials involving roughly 107,910 patients, the U.S. Food and Drug Administration found no evidence of an increased risk of suicidal thoughts or behavior and asked that related warning language be removed from GLP-1 labeling, while still encouraging ongoing monitoring.

European regulators landed in the same place. The safety committee of the European Medicines Agency reached a consistent conclusion, finding no link between these medications and suicidal or self-injurious thoughts. The new study's signal of reduced self-harm fits comfortably alongside those reviews. Even so, the wider research remains mixed, which is exactly why careful trials still matter.

Transparency is part of reading any study well, especially one involving heavily marketed medications. This research was funded by the Sigrid Jusélius Foundation, with additional support noted from the Jane and Aatos Erkko Foundation and the Finnish Ministry of Social Affairs and Health. Several of the authors, including Professor Tiihonen, have taken part in research projects funded by the pharmaceutical company Janssen or have received fees from other drugmakers; one author, Mark Taylor, reported no competing interests. Full disclosures are published with the paper. None of this invalidates the work — it underwent peer review at a major journal — but it is the kind of detail that lets you weigh the findings with clear eyes.

This article is for general information and is not medical advice. Questions about Ozempic, other GLP-1 medications, or your own mental-health care are best worked through with a qualified healthcare professional who knows your history and can weigh the full picture with you. And if you or someone you care about is struggling or in crisis, support is available right now — in the United States, you can call or text 988 to reach the Suicide and Crisis Lifeline.

What this study offers is something quieter than a breakthrough and more useful than a headline: a large, well-built look at a real-world population, pointing to a possibility that researchers now want to test properly. That is science working the way it should, and it is a hopeful place to keep watching from.